1 active not recruiting, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Compugen Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer COM701, Normal Saline - Ovarian Cancer, Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Active not recruiting | Compugen Ltd | 60 | 2025-07-21 | 2026-10-06 |
| COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. COM701 in combination with BMS-986207 and nivolumab. - Endometrial Neoplasms, Ovarian Cancer | Phase 1 / Phase 2 | Completed | Compugen Ltd | 48 | 2020-08-31 | 2024-07-18 |
Ovarian Neoplasms (2) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1)
Nivolumab (1) · Saline Solution (1)
United States (2) · France (1) · Israel (1)